{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:40:23Z","timestamp":1780645223581,"version":"3.54.1"},"reference-count":22,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>\n                    Rapidly growing mycobacteria (RGM) have been causing diseases with an increasing incidence that require long and difficult treatment. In this regard, it is a priority to seek rapid and low-cost optimization of therapeutic alternatives. Thus, our objective is to explore the combined activity between verapamil (VP) and the antimicrobials clarithromycin, amikacin, and clofazimine (CFZ) against\n                    <jats:italic toggle=\"yes\">Mycobacterium smegmatis<\/jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">Mycobacterium abscessus subsp. abscessus<\/jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">Mycobacterium abscessus subsp. massiliense<\/jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">Mycobacterium abscessus subsp. bolletii<\/jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">Mycobacterium chelonae<\/jats:italic>\n                    , and\n                    <jats:italic toggle=\"yes\">Mycobacterium fortuitum<\/jats:italic>\n                    . According to the checkerboard assay, it was observed that the best combination was between VP and CFZ, with synergistic activity on all tested bacteria. The time-killing assay demonstrated that VP improved the killing of CFZ and extended its inhibitory activity 16 times. In this sense, VP has modulating activity with most of the tested antimicrobials, especially with CFZ, and thus may have potential activity in preventing bacterial resistance that could be pointed out as a model for synergism in attempts at screening molecules for RGM infection treatments.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2024.0116","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T21:25:17Z","timestamp":1745443517000},"page":"162-167","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Verapamil Modulates Activity of Antimicrobials Against Rapidly Growing\n                    <i>Mycobacteria<\/i>"],"prefix":"10.1177","volume":"31","author":[{"given":"Andressa Ara\u00fajo","family":"Machado do Nascimento","sequence":"first","affiliation":[{"name":"Graduate Program in Biosciences and Physiopathology, State University Maring\u00e1, Maring\u00e1, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Trevisolli","family":"Palomo","sequence":"additional","affiliation":[{"name":"Graduate Program in Health Sciences, State University Maring\u00e1, Maring\u00e1, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regiane Bertin de Lima","family":"Scodro","sequence":"additional","affiliation":[{"name":"Graduate Program in Health Sciences, State University Maring\u00e1, Maring\u00e1, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katiany Rizzieri","family":"Caleffi-Ferracioli","sequence":"additional","affiliation":[{"name":"Graduate Program in Biosciences and Physiopathology, State University Maring\u00e1, Maring\u00e1, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7973-4098","authenticated-orcid":false,"given":"Vera Lucia Dias","family":"Siqueira","sequence":"additional","affiliation":[{"name":"Graduate Program in Biosciences and Physiopathology, State University Maring\u00e1, Maring\u00e1, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1836-2950","authenticated-orcid":false,"given":"Jean Eduardo","family":"Meneguello","sequence":"additional","affiliation":[{"name":"Graduate Program in Biosciences and Physiopathology, State University Maring\u00e1, Maring\u00e1, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosilene Fressatti","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Graduate Program in Biosciences and Physiopathology, State University Maring\u00e1, Maring\u00e1, Brazil."},{"name":"Graduate Program in Health Sciences, State University Maring\u00e1, Maring\u00e1, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa241"},{"issue":"7","key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/cid\/ciw877","article-title":"Two-phase hospital-associated outbreak of Mycobacterium abscessus: Investigation and mitigation","volume":"64","author":"Baker AW","year":"2017","unstructured":"Baker AW, , Lewis SS, , Alexander BD, et al. Two-phase hospital-associated outbreak of Mycobacterium abscessus: Investigation and mitigation. Clin Infect Dis, 2017; 64(7):902\u2013911; doi: 10.1093\/cid\/ciw877","journal-title":"Clin Infect Dis"},{"issue":"11","key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1128\/AEM.68.11.5318-5325.2002","article-title":"Occurrence of mycobacteria in water treatment lines and in water distribution systems","volume":"68","author":"Le Dantec C","year":"2002","unstructured":"Le Dantec C, , Duguet JP, , Montiel A, et al. Occurrence of mycobacteria in water treatment lines and in water distribution systems. Appl Environ Microbiol, 2002; 68(11):5318\u20135325; doi: 10.1128\/AEM.68.11.5318-5325.2002","journal-title":"Appl Environ Microbiol"},{"key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"659997","DOI":"10.3389\/fcimb.2021.659997","article-title":"Mycobacterium abscessus complex: A review of recent developments in an emerging pathogen","volume":"11","author":"Victoria L","year":"2021","unstructured":"Victoria L, , Gupta A, , G\u00f3mez JL, et al. Mycobacterium abscessus complex: A review of recent developments in an emerging pathogen. Front Cell Infect Microbiol, 2021; 11:659997; doi: 10.3389\/fcimb.2021.659997","journal-title":"Front Cell Infect Microbiol"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02615-15"},{"issue":"1","key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.chest.2021.07.035","article-title":"Treatment of Mycobacterium abscessus pulmonary disease","volume":"161","author":"Griffith DE","year":"2022","unstructured":"Griffith DE, , Daley CL. Treatment of Mycobacterium abscessus pulmonary disease. Chest, 2022; 161(1):64\u201375; doi: 10.1016\/j.chest.2021.07.035","journal-title":"Chest"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02052-16"},{"issue":"3","key":"e_1_3_5_9_2","article-title":"Assessment of Clofazimine and TB47 combination activity against Mycobacterium abscessus using a bioluminescent approach","volume":"64","author":"Liu Y","year":"2020","unstructured":"Liu Y, , Tan Y, , Islam MM, et al. Assessment of Clofazimine and TB47 combination activity against Mycobacterium abscessus using a bioluminescent approach. Antimicrob Agents Chemother, 2020; 64(3).","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/0896860820909702"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx147"},{"issue":"1","key":"e_1_3_5_12_2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley CL","year":"2020","unstructured":"Daley CL, , Iaccarino JM, , Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Eur Respir J, 2020; 56(1); doi: 10.1183\/13993003.00535-2020","journal-title":"Eur Respir J"},{"issue":"3","key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2217\/fmb-2018-0277","article-title":"Modulatory effects of verapamil in rifampicin activity against Mycobacterium tuberculosis","volume":"14","author":"Caleffi-Ferracioli KR","year":"2019","unstructured":"Caleffi-Ferracioli KR, , Cardoso RF, , De Souza JVP, et al. Modulatory effects of verapamil in rifampicin activity against Mycobacterium tuberculosis. Future Microbiol, 2019; 14(3):185\u2013194; doi: 10.2217\/fmb-2018-0277","journal-title":"Future Microbiol"},{"issue":"12","key":"e_1_3_5_14_2","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9122527","article-title":"Mycobacterium abscessus genetic determinants associated with the intrinsic resistance to antibiotics","volume":"9","author":"Gorzynski M","year":"2021","unstructured":"Gorzynski M, , Week T, , Jaramillo T, et al. Mycobacterium abscessus genetic determinants associated with the intrinsic resistance to antibiotics. Microorganisms, 2021; 9(12); doi: 10.3390\/microorganisms9122527","journal-title":"Microorganisms"},{"issue":"1","key":"e_1_3_5_15_2","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01316-18","article-title":"Mutations in the MAB_2299c TetR regulator confer cross-resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus","volume":"63","author":"Richard M","year":"2019","unstructured":"Richard M, , Guti\u00e9rrez AV, , Viljoen A, et al. Mutations in the MAB_2299c TetR regulator confer cross-resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus. Antimicrob Agents Chemother, 2019; 63(1); doi: 10.1128\/AAC.01316-18","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_16_2","volume-title":"CLSI M24 Susceptibility Testing of Mycobacteria, Nocardia Spp., and Other Aerobic Actinomycetes","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. CLSI M24 Susceptibility Testing of Mycobacteria, Nocardia Spp., and Other Aerobic Actinomycetes. 3rd ed. 2018.","edition":"3"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mimet.2015.02.007"},{"issue":"5","key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/jcla.21933","article-title":"Resazurin microtiter assay for clarithromycin susceptibility testing of clinical isolates of Mycobacterium abscessus group","volume":"30","author":"Garcia de Carvalho NF","year":"2016","unstructured":"Garcia de Carvalho NF, , Sato DN, , Pavan FR, et al. Resazurin microtiter assay for clarithromycin susceptibility testing of clinical isolates of Mycobacterium abscessus group. J Clin Lab Anal, 2016; 30(5):751\u2013755; doi: 10.1002\/jcla.21933","journal-title":"J Clin Lab Anal"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg301"},{"key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2180-11-35","article-title":"Ethidium bromide transport across Mycobacterium smegmatis cell-wall: Correlation with antibiotic resistance","volume":"11","author":"Rodrigues L","year":"2011","unstructured":"Rodrigues L, , Ramos J, , Couto I, et al. Ethidium bromide transport across Mycobacterium smegmatis cell-wall: Correlation with antibiotic resistance. BMC Microbiol, 2011; 11:35; doi: 10.1186\/1471-2180-11-35","journal-title":"BMC Microbiol"},{"key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jgar.2022.10.015","article-title":"Unraveling antibiotic resistance mechanisms in Mycobacterium abscessus: The potential role of efflux pumps","volume":"31","author":"Mudde SE","year":"2022","unstructured":"Mudde SE, , Schildkraut JA, , Ammerman NC, et al. Unraveling antibiotic resistance mechanisms in Mycobacterium abscessus: The potential role of efflux pumps. J Glob Antimicrob Resist, 2022; 31:345\u2013352; doi: 10.1016\/j.jgar.2022.10.015","journal-title":"J Glob Antimicrob Resist"},{"issue":"9","key":"e_1_3_5_22_2","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00705-19","article-title":"Verapamil improves the activity of bedaquiline against Mycobacterium abscessus in vitro and in macrophages","volume":"63","author":"Viljoen A","year":"2019","unstructured":"Viljoen A, , Raynaud C, , Johansen MD, et al. Verapamil improves the activity of bedaquiline against Mycobacterium abscessus in vitro and in macrophages. Antimicrob Agents Chemother, 2019; 63(9); doi: 10.1128\/AAC.00705-19","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_23_2","article-title":"A dose-finding study to guide use of Verapamil as an adjunctive therapy in tuberculosis","author":"Padmapriyadarsini C","year":"2023","unstructured":"Padmapriyadarsini C, , Szumowski JD, , Akbar N, et al. A dose-finding study to guide use of Verapamil as an adjunctive therapy in tuberculosis. medRxiv, 2023; doi: 10.1101\/2023.07.28.23293316","journal-title":"medRxiv"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2024.0116","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2024.0116","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2024.0116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:41:45Z","timestamp":1777668105000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2024.0116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1089\/mdr.2024.0116"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2024.0116","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}